We are live on ! Find out more
AC

Alexandria Capital Portfolio holdings

AUM $1.08B
1-Year Est. Return 29.48%
This Fund
S&P 500
This Quarter Est. Return
-0.02%
1 Year Est. Return
+29.48%
3 Year Est. Return
+66.81%
5 Year Est. Return
+127.84%
10 Year Est. Return
AUM
$1.08B
AUM Growth
+$1.6M
Cap. Flow
-$10.6M
Cap. Flow %
-0.98%
Top 10 Hldgs %
25.11%
Holding
269
New
3
Increased
97
Reduced
102
Closed
15

Sector Composition

Rank Sector Weight
1 Technology 20.34%
2 Healthcare 9.51%
3 Communication Services 8.96%
4 Financials 7.57%
5 Consumer Discretionary 4.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IJR icon
251
iShares Core S&P Small-Cap ETF
IJR
$112B
-1,898
Closed -$214K
MFA
252
MFA Financial
MFA
$933M
-5,296
Closed -$97K
NKTR icon
253
Nektar Therapeutics
NKTR
$2.58B
-1,671
Closed -$430K
PANL icon
254
Pangaea Logistics
PANL
$485M
-10,000
Closed -$50K
RCKY icon
255
Rocky Brands
RCKY
$369M
-4,224
Closed -$235K
TPR icon
256
Tapestry
TPR
$32.8B
-5,421
Closed -$236K
UBER icon
257
Uber
UBER
$153B
-4,000
Closed -$200K
DRNA
258
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
-8,000
Closed -$299K
KSU
259
DELISTED
Kansas City Southern
KSU
-720
Closed -$204K

Similar funds

Alexandria Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Alexandria Capital held 269 positions worth $1.08B, up 0.15% from $1.08B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Alexandria Capital's Q3 2021 filing shows 3 new, 97 increased, 102 reduced and 15 closed positions. Its largest new stake was Illinois Tool Works: 1,032 shares worth $213K. The largest sale was Alnylam Pharmaceuticals, an estimated $651K.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Communication Services.

  • Alexandria Capital's largest Q3 2021 buy was Illinois Tool Works: 1,032 shares worth $213K.
  • Alexandria Capital added most to iShares MSCI Emerging Markets ex China ETF in Q3 2021, an estimated $1.59M increase.
  • Alexandria Capital's biggest Q3 2021 reduction was Alnylam Pharmaceuticals, cutting an estimated $651K.
  • Alexandria Capital fully exited Nektar Therapeutics in Q3 2021, selling an estimated $430K.
  • Alexandria Capital's ten largest holdings make up 25% of its $1.08B portfolio in Q3 2021.
  • Alexandria Capital opened 3 new positions and closed 15 in Q3 2021.
  • Alexandria Capital's portfolio value rose 0.15% quarter-over-quarter to $1.08B.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.